



27 August 2015

ASX ANNOUNCEMENT

APPENDIX 4E - Alteration

Brisbane, Australia – **ImpediMed Limited** (ASX: IPD) (“the Company”), announce that further to the release of Appendix 4E on 26 August 2015 an amended version has been resubmitted to the ASX.

Changes as follows:

Page one – The original document had brackets around the revenue numbers. These have now been deleted.

Cherrell Hirst AO
Chairman

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

ImpediMed Limited - Appendix 4E			
ABN 65 089 705 144			
Preliminary final report			
1	Current Financial Period Ended:	30 June 2015	
	Previous Corresponding Reporting Period:	30 June 2014	
The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2015 ("2015 Financial Report") and any public announcements made by ImpediMed Limited and its controlled entities during the year in accordance with continuous disclosure obligations arising under the ASX Listing Rules.			
2	Results for announcement to the market		
		Current reporting period \$000	Previous corresponding period \$000
2.1	Revenue from ordinary activities	\$ 4,927	\$ 3,578
	Increase (decrease) in revenue (\$000):		\$ 1,349
	Percentage increase (decrease):		38%
Note : Revenue related to goods and services increased for the year ended 30 June 2015 to \$4.9 million (2014 \$3.6 million), an increase of \$1.3 million year over year. The change by operating segment was an increase of \$0.5 million in medical, and a \$0.8 million increase in test & measurement. The \$0.5 million increase in the medical segment was due to a \$0.1 million increase in body composition and veterinary products, while total lymphoedema product revenue for the Group increased by \$0.4 million, or 28% year over year.			
2.2	Profit/(loss) from ordinary activities after tax attributable to members	(14,797)	(7,935)
	Increase/(decrease) in profit from ordinary activities after tax attributable to members (\$000):		\$ (6,862)
	Percentage increase/(decrease):		-86%
Note : Refer to the Directors' Report for a more extensive analysis; however, in summary, in addition to the increase in revenue above:			
- salaries and benefits expense increased by \$4.4 million			
- research and development expenses increased by \$0.6 million			
- consultants and professional fees increased by \$0.5 million			
- advertising and promotion expense increased by \$0.8 million			
- travel expense increased by \$0.5 million			
2.3	Net profit/(loss) for the period attributable to members	(14,797)	(7,935)
	Increase/(decrease) in net profit for the period attributable to members (\$000):		\$ (6,862)
	Percentage increase/(decrease):		-86%
Note: Refer to 2.2 above and to the Directors' Report in the 2015 Financial Report.			
3	Dividends		
3.1	Dividends	Nil	
There were no dividends declared and paid during the reporting period on ordinary shares.			
There were no dividends proposed and not yet recognised as a liability during the reporting period.			
3.2	Dividend Record Date	Not applicable	

4 Financial Statements		
4.1 Statement of comprehensive income		
Refer to the Consolidated Statement of Comprehensive Income in the 2015 Financial Report.		
4.2 Statement of financial position		
Refer to the Consolidated Balance Sheet in the 2015 Financial Report.		
4.3 Statement of cash flows		
Refer to the Consolidated Cash Flow Statement in the 2015 Financial Report.		
4.4 Statement of retained earnings		
Refer to the Consolidated Statement of Changes in Equity in the 2015 Financial Report for movements in retained earnings.		
5 Net tangible assets per security		
	Current reporting period	Previous corresponding period
5.1 Net tangible assets (\$000)	32,429	11,567
Issued share capital at reporting date (\$000)	147,349	116,593
	Current reporting period	Previous corresponding period
Number of shares on issue at reporting date	293,287,840	238,672,802
Net tangible assets per security	\$ 0.11	\$ 0.05
6 Earnings per security		
	Current reporting period	Previous corresponding period
6.1 Weighted average number of ordinary shares (excluding reserved shares) for basic earnings per share (EPS)	268,288,850	195,605,935
Loss per share from continued operations		
Basic EPS	\$ -	\$ -
Loss per share from profit attributable to ordinary shares		
Basic EPS	\$ -	\$ -
Diluted earnings per share has been determined to be the same as basic earnings per share as the actual calculation is anti-dilutive for both periods presented.		
Refer to Note 1 - Earnings per share in the Annual Financial Report for the year ended 30 June 2015 for additional information pertaining to EPS for the current reporting period.		
7 Acquisitions and divestments		
There were no entities over which control has been gained or lost during the reporting period.		
8 Foreign entities		
Not applicable.		
9 Associates and joint ventures		
Not applicable.		
10 Commentary on results for the financial year		
Refer to the Annual Financial Report for the year ended 30 June 2015.		
11 Results of segments		
Refer to Note 3 - Segment reporting in the Annual Financial Report for the year ended 30 June 2015 for additional information pertaining to segment results for the current reporting period.		
12 Audited Report		
The report is based on audited accounts which are not subject to dispute, modification, or qualification.		